The Global Head and Neck Cancer drugs market size stood at USD 1.49 billion in 2019 and is expected to rise to USD 2.81 billion by the end of 2028 exhibiting a CAGR of approximately 7.3% during the forecast period.
According to the Swedish Head and Neck Cancer Register, 2.3% of all cancer cases can be attributed to Head and Neck Cancers which accounts for 1,500 cases per year. Out of all the sites, Oral Cavity is the most common site of occurrence followed by Oropharynx. The increase in incidence of Oropharyngeal cancer can be attributed to the rise in Human Papilloma Virus induced cancers. Squamous Cell Carcinoma is the most common histological type among all the cancers that occur in the region.
Head & neck cancers include a number of different malignant tumours that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. They have wide range of risk factors like smoking, tobacco consumption, unhealthy lifestyle etc. These cancers have a direct impact on the mental health of the patient, severely hampering the quality of life. This offers innumerable opportunities to the manufacturers of Head and Neck Cancer drugs in the country.
The Swedish Head and Neck Cancer Drugs market is majorly driven by the increase in the prevalence of Head and Neck Cancers. This is due to the increase in unhealthy lifestyle factors like smoking and consumption of tobacco and alcohol.
The Government initiatives to prevent HPV caused Oral Cancer through vaccination strategies further boost market growth. This is compounded by increased per capita spending on healthcare.
Improved awareness among the people have paved way for early diagnosis and treatment, thus propelling market growth.